Ademetionine in Obstructive Hypertrophic Cardiomyopathy
Safety and Efficacy of Ademetionine in Patients With Obstructive Hypertrophic Cardiomyopathy: A Multicenter, Double-Blind, Randomized Controlled, Phase 2 Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Yu Zhang
- Phone Number: +86 19801288531
- Email: dr_yuzhang@126.com
Study Locations
-
-
-
Beijing, China
- Recruiting
- Fuwai Hospital
-
Contact:
- Lei Song
- Phone Number: 19801288531
- Email: songlqd@126.com
-
Shanghai, China
- Recruiting
- Zhongshan Hospital, Shanghai Medical College of Fudan University
-
Contact:
- Ruizhen Chen
- Phone Number: 13774462136
- Email: chen.ruizhen@zs-hospital.sh.cn
-
Xinjiang, China
- Not yet recruiting
- The First Affiliated Hospital of Xinjiang Medical University
-
Contact:
- Yingying Zheng
- Phone Number: 15214804944
- Email: zhengying527@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Meet the diagnostic criteria for HCM.
- Age ≥ 18 years at screening.
- LVEF ≥ 50% at screening.
- Echocardiography demonstrates a resting or provoked LVOTG ≥ 30 mmHg at screening.
- NYHA Functional Class II-III at screening.
- Able to perform CPET.
- Patients receiving treatment with β-blockers or non-dihydropyridine calcium channel blockers should have been on a stable dose for at least 6 weeks prior to randomization and are expected to maintain the same medication during the trial. Who have previously received cardiac myosin inhibitors (e.g., Mavacamten) must discontinue the treatment for at least 8 weeks prior to randomization.
- Willing and able to sign the informed consent form and comply with all scheduled study visits.
Exclusion Criteria:
- History of severe hypersensitivity to any component of Ademetionine 1,4-Butanedisulfonate Enteric-coated Tablets.
- History of psychiatric disorders, or current use of antidepressants such as clomipramine.
- Planned for any surgical (including septal reduction therapy) or interventional procedure during the trial period.
- Planned use of cardiac myosin inhibitors (e.g., Mavacamten) during the trial period.
- Currently pregnant or planning pregnancy.
- Currently participation in another drug or device clinical trial.
- History of any other disease with a life expectancy of less than 1 year.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Placebo group
|
The placebo is a starch tablet identical in appearance, odor, and other physical properties.
|
|
Active Comparator: Ademetionine group
|
Ademetionine 1,4-Butanedisulfonate is the currently available marketed oral pharmaceutical formulation of S-adenosylmethionine. Its brand name is Ximeixin in China.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Change in pVO₂ by CPET from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
From enrollment to the end of treatment at 16 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Proportion of participants with ≥1 class improvement in NYHA Functional Class from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in KCCQ-CSS from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in provoked left ventricular outflow tract gradient from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in left ventricular mass index from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in left atrial volume index from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in E/e' from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in VE/VCO₂ slope by CPET from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
From enrollment to the end of treatment at 16 weeks
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in maximal left ventricular wall thickness from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
Exploratory endpoint
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in NT-proBNP from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
Exploratory endpoint
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in hs-cTnI from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
Exploratory endpoint
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in hs-cTnT from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
Exploratory endpoint
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in SF-36 from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
Exploratory endpoint
|
From enrollment to the end of treatment at 16 weeks
|
|
Change in HCMSQ from baseline to Week 16
Time Frame: From enrollment to the end of treatment at 16 weeks
|
Exploratory endpoint
|
From enrollment to the end of treatment at 16 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2025-ZX068
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.